Company news
Gensight Biologics SA news in 2025
Gensight Biologics SA's news releases, calls and decks from 2025, newest first.
GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million
December 29, 2025
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
December 22, 2025
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
December 22, 2025
GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France
December 2, 2025
Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics
November 19, 2025
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million
November 13, 2025
GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million
November 10, 2025
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
October 30, 2025
GenSight Biologics Reports Cash Position as of September 30, 2025
October 7, 2025
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million
October 1, 2025
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
September 29, 2025
GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million
September 26, 2025
GenSight Biologics Postpones Release of 2025 Half-Year Financial Results
August 28, 2025
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
August 20, 2025
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
July 17, 2025
GenSight Biologics Reports Cash Position as of June 30, 2025
July 8, 2025
GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement
July 3, 2025
GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million
July 1, 2025
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
June 26, 2025
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
June 12, 2025
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
May 13, 2025
Decks in 2025
- Investor Presentation (May 2025)
Investor deck · 26 slides · May 2025